STRENGTHENING COOPERATION ON HEALTH TECHNOLOGY ASSESSMENT

WHAT IS HTA?

Is this medicine a better treatment for a certain disease?
Will this new scanner really lead to a better diagnosis?
Does this innovative surgery improve the patient’s treatment?

HEALTH TECHNOLOGY ASSESSMENT:
procedure for assessing the added value of new medicines and medical devices

WHAT’S NEW?

- Common European assessment methods
- Shared data and expertise
- Common procedures across the EU

WHAT ARE THE BENEFITS

- Higher level of human health protection
- Faster market access for innovative products
- More transparency for patients and producers
- No more duplication of work for health authorities and industry

AREAS OF HTA COOPERATION

- Joint clinical assessments
- Scientific consultations on the development of new products
- Mapping of emerging health technologies
- Voluntary cooperation on other areas (e.g. surgical procedures)

NEW MEDICINES

EU ASSESSMENT (jointly done by the Member States)

- CLINICAL ASSESSMENT (benefits compared to existing treatments)
- NON-CLINICAL ASSESSMENT (economic, social and ethical aspects)

NATIONAL ASSESSMENT

National decisions on pricing and reimbursement

NEW MEDICAL DEVICES

- High-risk devices with high impact on patients, public health and EU health systems
- CLINICAL ASSESSMENT (benefits compared to existing treatments)
- NON-CLINICAL ASSESSMENT (economic, social and ethical aspects)

TIMELINE

31 JANUARY 2018
ADOPTION OF THE COMMISSION PROPOSAL

2019
ADOPTION BY THE PARLIAMENT AND THE COUNCIL

+3 YEARS
START OF APPLICATION OF THE EU REGULATION

+3 YEARS
END OF THE TRANSITIONAL PERIOD FOR EU MEMBER STATES

https://ec.europa.eu/health/technology_assessment/policy_en
@EU_Health